Neuronal nicotinic acetylcholine receptor alpha4beta2 (α4β2 nAChR) (α4β2 nAChR)

The neuronal nicotinic acetylcholine receptor alpha4beta2 (α4β2 nAChR) is a pentameric ligand-gated ion channel and the most prevalent high-affinity nicotine-binding site in the mammalian brain (1.3.1, 1.3.5). It primarily exists in two stoichiometric forms, (α4)2(β2)3 and (α4)3(β2)2, which exhibit distinct pharmacological sensitivities and ion conductances (1.1.1, 1.4.1). This receptor subtype is a key modulator of neurotransmission, particularly influencing the release of dopamine, GABA, and glutamate in circuits associated with reward, cognition, and mood (1.3.3, 1.4.2). Due to its central role in the mesolimbic dopamine system, it is the primary target for smoking cessation therapies, where partial agonists like varenicline help mitigate withdrawal symptoms and block nicotine's reinforcing effects (1.2.2, 1.2.4). Beyond addiction, α4β2 receptors are implicated in the pathophysiology of Alzheimer's disease, Parkinson's disease, and certain forms of epilepsy, making them a significant focus for cognitive enhancers and neuroprotective agents (1.3.3, 1.4.3). Therapeutic challenges include achieving subtype selectivity to avoid off-target effects on other nicotinic receptors and managing side effects such as nausea and sleep disturbances (1.2.2).

Other names

α4β2 receptorAlpha4beta2 nicotinic receptorNeuronal acetylcholine receptor alpha4beta2High-affinity nicotine binding siteCHRNA4/CHRNB2 heteromer

Partial agonism, full agonism, antagonism, and positive allosteric modulation.